Inclusion Criteria:  Written Informed Consent consistent with International Conference on Harmonization Tripartite Guideline for Good Clinical Practice (ICH-GCP) and local laws signed prior to entry into the study Male or female ≥ 18 years of age at the time of consent SARS-CoV-2 positive confirmed by a positive serology or PCR or antigen test COVID-19 induced hypoxemia or reduced oxygen saturation requiring treatment with supplemental oxygen. COVID-19 hospital discharge date or outpatient COVID-19 infection within 24 weeks of enrollment  Exclusion Criteria:  Diagnosed with Fibrotic Interstitial Lung Disease (ILD) prior to COVID-19 infection. Prior treatment with an antifibrotic agent, including nintedanib or pirfenidone Pregnant women or women planning on becoming pregnant in the next 12 months Patients planned for discharge from the hospital to hospice Patients with significant cognitive impairment